• Japanese
  • Korean
  • Chinese
Cover Image

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Progressive Ataxia

The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

Progressive ataxia treatments are expected to have a value of $356.4 million in 2012 and $620.7 million in 2017, a CAGR of 11.7%.

Treatments for Machado-Joseph disease should total $158.4 million in 2012 and $273.5 million in 2017, a CAGR of 11.5%.

SUMMARY FIGURE
GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS,
2010-2017 ($ MILLIONS)

Source: BCC Research

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for treatments of neurodegenerative (i.e., progressive ataxia and weakness) disorders. The key objective is to present a comprehensive analysis and the future direction of treatments for these disorders as the market efforts toward drug and therapy development evolve.

This report explores present and future strategies within the progressive ataxia and weakness disorders market, which includes treatments and therapies for dysfunctions, including progressive ataxia and progressive weakness disorder syndromes. The market's improvisation, setbacks and needs are also discussed. The comparisons, usage, advantages and disadvantages of different types of technologies, including small-molecule and monoclonal antibodies, are also presented.

A detailed analysis of the industry structure has been conducted. Revenues are broken down by the neurodegenerative dysfunction. Sales figures are estimated for the five-year period from 2012 through 2017.

The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of progressive ataxia and weakness disorders as well as collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technology development is providing modifying therapies for the late stages of these disorders. Collaborations among research institutes and pharmaceutical companies are becoming more common, as state-of-the-art technology is being explored to develop more-efficient products and therapies.

R&D spending, increasing competition, patent expiries and new technologies are shifting the market in a new direction. The market's overall revenue has increased from 2009 to 2011, and it continues to show growth, as new advancements, product launches and collaborations will have positive influences for the foreseeable future. This study looks at most of the systems affected by these factors.

Acquisition strategies and company collaborations are also covered in this report. This study discusses the strength and weaknesses of each technology in light of the new developments, growing competition and changing customer needs.

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. These included manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease-sector industries. Data were gathered from various industry sources. BCC spoke with officials within the industry and also reviewed newsletters, company literature and product literature, as well as a host of technical articles, journals, indices and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry has carried out this study. Its project manager is Shalini S. Dewan, who holds a Master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. She has covered such research topics as compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work, and she has collaborated with top companies in India and in the U.S.

Table of Contents

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Progressive Ataxia

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter - 2: EXECUTIVE SUMMARY

  • Table Summary: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017
  • Figure Summary: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017

Chapter - 3: OVERVIEW

  • DEFINITIONS
  • CLASSIFICATION
  • PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS
  • DIAGNOSTIC TESTS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS

Chapter - 4: REGULATORY ASPECTS

  • DRUG APPROVALS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS
  • REGULATORY DEVELOPMENTS OF PRODUCTS USED TO TREAT PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS

Chapter - 5: NEW DEVELOPMENTS

  • Table 6: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012
  • Table 7: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011
  • Table 8: NEW DEVELOPMENTS IN THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010

Chapter - 6: GLOBAL MARKETS

  • MARKETS BY DYSFUNCTION
  • MARKETS BY DISORDERS
  • MARKET BY REGIONS
  • MARKETS BY TECHNOLOGY

Chapter - 7: PROGRESSIVE ATAXIA SYNDROME MARKET

  • MARKET BY DISEASE TYPE
  • MARKET BY REGION
  • MARKET BY TECHNOLOGY
  • INDUSTRY STRUCTURE

Chapter - 8: PATENT ANALYSIS

  • PATENTS BY YEAR
  • PATENTS BY DISEASE CATEGORY
  • PATENTS BY DISEASE TYPE
  • PATENTS BY COUNTRY
  • PATENTS BY COMPANY
  • PATENTS BY ASSIGNEE

Chapter - 9: CURRENT SITUATION

  • MARKET TRENDS
  • ADDITIONAL DRIVERS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS DRUG MARKET
  • FACTORS GOVERNING THE MARKET
  • COLLABORATIONS, MERGERS AND ACQUISITIONS

Chapter - 10: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ACORDA THERAPEUTICS INC.
  • ACTAVIS ELIZABETH
  • ALLON THERAPEUTICS INC
  • AMERICAN REGENT INC.
  • APOTEX INC.
  • APOTHECA, INC.
  • APP PHARMACEUTICALS
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA GMBH
  • AUROBINDO PHARMA LTD
  • BAXTER INTERNATIONAL INC.
  • BIOGEN IDEC
  • BOEHRINGER INGELHEIM LTD.
  • BRISTOL-MYERS SQUIBB
  • BRYANT RANCH PREPACK
  • CADILA HEALTHCARE LTD.
  • CARACO PHARMACEUTICAL LABORATORIES
  • CARDINAL HEALTH
  • COGNITION PHARMACEUTICALS LLC
  • CSL BEHRING
  • DR. REDDY'S LABORATORIES LIMITED
  • EISAI CO. LTD
  • ELAN PHARMA INTERNATIONAL LIMITED
  • ELI LILLY AND COMPANY
  • EMD MILLIPORE HEADQUARTERS
  • ENDO PHARMACEUTICALS INC
  • GLAXOSMITHKLINE PLC.
  • GLENMARK GENERICS LIMITED
  • H. LUNDBECK A/S
  • HAMELN PHARMACEUTICALS LTD
  • HOSPIRA INC.
  • INTELLECT NEUROSCIENCES INC.
  • JAZZ PHARMACEUTICALS PLC.
  • LEXICON PHARMACEUTICALS INC.
  • MAJOR PHARMACEUTICALS
  • MERCK SERONO
  • MERCK SHARP & DOHME LIMITED
  • MERZ PHARMA GMBH & CO KGAA
  • MOMENTA PHARMACEUTICALS
  • MYLAN PHARMACEUTICALS
  • NEUREN PHARMACEUTICALS LTD.
  • NEUROSEARCH A/S
  • NOSCIRA, S.A.
  • NOVARTIS AG
  • ORCHID CHEMICALS & PHARMACEUTICALS LTD.
  • ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.
  • PAR PHARMACEUTICALS
  • PERRIGO COMPANY
  • PFIZER INC.
  • PHARNEXT
  • PHYSICIANS TOTAL CARE, INC.
  • PLIVA HRVATSKA D.O.O.
  • PROMETHEUS
  • RANBAXY LABORATORIES LIMITED
  • ROCHE HOLDING LTD
  • ROXANE LABORATORIES INC.
  • SANDOZ INTERNATIONAL GMBH
  • SANOFI
  • SANTHERA PHARMACEUTICALS
  • SHIONOGI & CO.
  • SUN PHARMA
  • TAJ PHARMACEUTICALS LIMITED
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • TERCICA, INC
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • TORRENT PHARMA
  • UCB S.A.
  • UDL LABORATORIES
  • UPSHER-SMITH LABORATORIES
  • WATSON PHARMACEUTICALS INC.
  • WEST-WARD PHARMACEUTICAL

Chapter - 11: APPENDIX I: ABBREVIATIONS

List of Tables

  • Summary Table: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017
    • Table 1: CLASSIFICATION BY PRIMARY DYSFUNCTION
    • Table 2: ABBREVIATED APPROVALS AND NEW DRUG APPROVALS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012
    • Table 3: NEW DRUG APPLICATIONS FOR THE PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS
    • Table 4: SAFETY ALERTS, 2010-MARCH 2012
    • Table 5: RECALLS FOR DRUGS USED TO TREAT PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010 - MARCH 2012
    • Table 6: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012
    • Table 7: NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011
    • Table 8: NEW DEVELOPMENTS IN THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010
    • Table 9: GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017
    • Table 10: MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011
    • Table 11: GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017
    • Table 12: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011
    • Table 13: MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, THROUGH 2017
    • Table 14: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011
    • Table 15: GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, THROUGH 2017
    • Table 16: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011
    • Table 17: SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA BY DISEASE TYPE, THROUGH 2017
    • Table 18: PROGRESSIVE ATAXIA DRUG MARKET BY DISEASE TYPE, 2011
    • Table 19: PROGRESSIVE ATAXIA DRUG MARKET BY REGION, THROUGH 2017
    • Table 20: PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2011
    • Table 21: FRIEDREICH'S ATAXIA DRUG MARKET BY REGION, THROUGH 2017
    • Table 22: GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUG MARKET BY REGION, THROUGH 2017
    • Table 23: MACHADO-JOSEPH DISEASE DRUG MARKET BY REGION, THROUGH 2017
    • Table 24: PROGRESSIVE ATAXIA DRUG MARKET BY TECHNOLOGY, THROUGH 2017
    • Table 25: PROGRESSIVE ATAXIA DRUGS SHARE BY TECHNOLOGY, 2011
    • Table 26: LEADING MANUFACTURERS AND SUPPLIERS OF FRIEDREICH'S ATAXIA DRUGS AND THERAPIES
    • Table 27: MARKET SHARES FOR MANUFACTURERS AND DISTRIBUTORS OF FRIEDREICH'S ATAXIA DRUGS, 2011
    • Table 28: LEADING MANUFACTURERS AND SUPPLIERS OF GERSTMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS AND THERAPIES
    • Table 29: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS, 2011
    • Table 30: LEADING MANUFACTURERS AND SUPPLIERS OF MACHADO-JOSEPH DISEASE DRUGS AND THERAPIES
    • Table 31: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MACHADO-JOSEPH DISEASE DRUGS, 2011
    • Table 32: TOTAL NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012
    • Table 33: PATENTS BY DISEASE CATEGORY, 2010-MARCH 2012
    • Table 34: PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010 - 2012
    • Table 35: PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT THE ON BRAIN AND SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010 - 2012
    • Table 36: U.S. PATENTS BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES, 2010 - 2012
    • Table 37: PATENT SHARES BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES, 2010 - 2012
    • Table 38: U.S. PATENTS BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010-2012
    • Table 39: PATENT SHARES BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010 - 2012
    • Table 40: U.S. PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY COMPANY, 2010 - 2012
    • Table 41: U.S. PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES BY COMPANY, 2010-2012
    • Table 42: PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY ASSIGNEE, 2010 - 2012
    • Table 43: PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES BY ASSIGNEE, 2010 - 2012

List of Figures

  • Summary Figure: GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017
    • Figure 1: GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, 2010-2017
    • Figure 2: MARKET SHARE OF DRUG USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011
    • Figure 3: GLOBAL SALES OF DRUG PRODUCT FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017
    • Figure 4: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011
    • Figure 5: MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2010-2017
    • Figure 6: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011
    • Figure 7: GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2010-2017
    • Figure 8: MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011
    • Figure 9: SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA BY DISEASE TYPE, 2010-2017
    • Figure 10: PROGRESSIVE ATAXIA DRUG MARKET BY DISEASE TYPE, 2011
    • Figure 11: PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2010-2017
    • Figure 12: PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2011
    • Figure 13: FRIEDREICH'S ATAXIA DRUG MARKET BY REGION, 2010-2017
    • Figure 14: GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUG MARKET BY REGION, 2010-2017
    • Figure 15: MACHADO-JOSEPH DISEASE DRUG MARKET BY REGION, 2010-2017
    • Figure 16: PROGRESSIVE ATAXIA DRUG MARKET BY TECHNOLOGY, 2010-2017
    • Figure 17: PROGRESSIVE ATAXIA DRUGS SHARE BY TECHNOLOGY, 2011
    • Figure 18: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF FRIEDREICH'S ATAXIA DRUGS, 2011
    • Figure 19: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS, 2011
    • Figure 20: MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MACHADO-JOSEPH DISEASE DRUGS, 2011
    • Figure 21: NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012
    • Figure 22: PATENTS BY DISEASE CATEGORY, 2010-MARCH 2012
    • Figure 23: PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010-2012
    • Figure 24: PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON BRAIN AND SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010-2012
Show More
Pricing
Get Notified
Email me when related reports are published